NEW YORK, NY -- (MARKET WIRE) -- October 09, 2006 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D) today announced that it has developed a next-generation AIDS formulation which includes both immune modulator functions and anti-viral activity. This formulation, based on Amazon’s Phase I/II developmental drug AMZ0026, includes additional active ingredients found in a plant which are known in the literature to posses anti-viral properties.
